Diligence memo · auto-generated · as of July 2, 2026

Heart Test Laboratories, Inc.

Heart Test Laboratories, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Heart Test Laboratories, Inc. operates in Other Health Care, based in SOUTHLAKE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Heart Test Laboratories, Inc. has raised $35M in disclosed capital across 13 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $7.0M on 2016-07-01.

Most recent recorded round closed around 2023-11-16.

Valuation (modeled)modeled

Provath models Heart Test Laboratories, Inc. at approximately $5.6M (range $1.2M–$14M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.15× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era. Issuer reports $0–$1M revenue while modeled below niche peers.

Financing rhythm & timingmixed

Historic cadence: a new round about every 14 months.

Last raise 2.6 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 1.7× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 90% of Other Health Care peers (5377 compared).

Modeled value ranks above 23% of those peers.

Closest niche peers: CareHarmony, Inc., Dragonfly Endoscopy Inc., NuvoAir Holdings, Inc., Post Acute Recovery, Inc., Micro Interventional Devices, Inc..

Peoplefiled

21 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.